A phase Ib TATTON trial of durvalumab plus osimertinib for first- and second-line treatment of EGFR-positive NSCLC demonstrated a high incidence of interstitial lung disease [64], and the study was suspended. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.